Skip to main content
SpringerLink
Log in

Clinical Pharmacokinetic Monitoring of Leflunomide in Renal Transplant Recipients with BK Virus Reactivation: A Review of the Literature

  • Review Article
  • Published:
Clinical Pharmacokinetics Aims and scope Submit manuscript

Abstract

Leflunomide is an immunosuppressive drug with in vitro and initial observational evidence of antiviral activity against BK virus (BKV), a pathogen that causes opportunistic infection upon reactivation in renal transplant recipients. Leflunomide is considered an ancillary option to immunosuppression reduction in the management of BKV reactivation. Plasma or blood concentrations of teriflunomide, the active metabolite of leflunomide, are commonly monitored because of high leflunomide doses being used, known inter-individual variability in pharmacokinetics, and hepatotoxicity risk. However, the utility of clinical pharmacokinetic monitoring for leflunomide is as yet unclear. A literature search of MEDLINE (1946–December 2016), EMBASE (1974–December 2016), the CENTRAL database, and Google Scholar was performed to identify relevant English-language articles. Further articles were identified from references in relevant literature. A previously published 9-step decision-making algorithm was used to assess the available literature and determine the utility of clinical pharmacokinetic monitoring for leflunomide. Teriflunomide is readily measurable in the plasma or blood, but a clear relationship between concentration and efficacy or toxicity is lacking, and its therapeutic range is not well-established. Efficacy and toxicity endpoints such as renal function and BKV clearance can be readily assessed without measuring teriflunomide concentrations. Pharmacokinetic parameters are affected by genetic polymorphisms in cytochrome P450 CYP2C19 and ABCG2 genes. Therefore, routine clinical pharmacokinetic monitoring of leflunomide cannot be recommended based on current available evidence. However, it may provide clinical benefit in difficult situations when patients demonstrate a lack of therapeutic response or exhibit signs of drug toxicity.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group. KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant. 2009;9 Suppl 3:S1–155.

  2. (CIHI) CI for HI. 2015 CORR report: treatment of end-stage organ failure in Canada, 2004 to 2013. 2015. https://secure.cihi.ca/estore/productFamily.htm?locale=en&pf=PFC2864&lang=en. Accessed 17 Nov 2016.

  3. Womer KL, Kaplan B. Recent developments in kidney transplantation—a critical assessment. Am J Transplant. 2009;9(6):1265–71.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Yabu JM, Vincenti F. Kidney Transplantation: the ideal immunosuppression regimen. Adv Chronic Kidney Dis. 2009;16(4):226–33.

    Article  PubMed  Google Scholar 

  5. Dharnidharka VR, Abdulnour HA, Araya CE. The BK virus in renal transplant recipients—review of pathogenesis, diagnosis, and treatment. Pediatr Nephrol. 2010;26(10):1763–74.

    Article  PubMed  Google Scholar 

  6. Balba GP, Javaid B, Timpone JG Jr. BK polyomavirus infection in the renal transplant recipient. Infect Dis Clin N Am. 2013;27(2):271–83.

    Article  Google Scholar 

  7. Bazin C. Leflunomide an immunosuppressive drug for antiviral purpose in treatment for BK virus-associated nephropathy after kidney transplantation. In: Arbuthnot P, editor. Antiviral drugs—aspects of clinical use and recent advances. InTech; 2012. http://www.intechopen.com/books/antiviral-drugs-aspects-of-clinical-use-and-recent-advances/leflunomide-an-immunosuppressive-drug-for-antiviral-purpose-in-treatment-for-bk-virus-nephropathy-af. Accessed 27 Jan 2016.

  8. Saad ER, Bresnahan BA, Cohen EP, Lu N, Orentas RJ, Vasudev B, et al. Successful treatment of BK viremia using reduction in immunosuppression without antiviral therapy. Transplantation. 2008;85(6):850–4.

    Article  CAS  PubMed  Google Scholar 

  9. Vasudev B, Hariharan S, Hussain SA, Zhu Y-R, Bresnahan BA, Cohen EP. BK virus nephritis: risk factors, timing, and outcome in renal transplant recipients. Kidney Int. 2005;68(4):1834–9.

    Article  PubMed  Google Scholar 

  10. Funk GA, Steiger J, Hirsch HH. Rapid dynamics of polyomavirus type BK in renal transplant recipients. J Infect Dis. 2006;193(1):80–7.

    Article  PubMed  Google Scholar 

  11. Ensom MHH, Davis GA, Cropp CD, Ensom RJ. Clinical pharmacokinetics in the 21st century. Does the evidence support definitive outcomes? Clin Pharmacokinet. 1998;34(4):265–79.

    Article  CAS  PubMed  Google Scholar 

  12. Rozman DB. Clinical pharmacokinetics of leflunomide. Clin Pharmacokinet. 2012;41(6):421–30.

    Article  Google Scholar 

  13. Oh J, O’Connor PW. Teriflunomide in the treatment of multiple sclerosis: current evidence and future prospects. Ther Adv Neurol Disord. 2014;7(5):239–52.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Kalgutkar AS, Nguyen HT, Vaz ADN, Doan A, Dalvie DK, McLeod DG, et al. In vitro metabolism studies on the isoxazole ring scission in the anti-inflammatory agent lefluonomide to its active alpha-cyanoenol metabolite A771726: mechanistic similarities with the cytochrome P450-catalyzed dehydration of aldoximes. Drug Metab Dispos. 2003;31(10):1240–50.

    Article  CAS  PubMed  Google Scholar 

  15. Center for Drug Evaluation and Research. Drug approval package: Aubagio (Teriflunomide) tablets. Clinical Pharmacology and Biopharmaceutics Review(s): NDA992; 2011. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202992Orig1s000SumR.pdf. Accessed 18 Feb 2017.

  16. Hopkins A, Wiese M, Proudman S, O’Doherty C, Foster D, Upton R. Semiphysiologically based pharmacokinetic model of leflunomide disposition in rheumatoid arthritis patients. CPT Pharmacomet Syst Pharmacol. 2015;4(6):362–71.

    Article  CAS  Google Scholar 

  17. Bergner R, Peters L, Schmitt V, Löffler C. Leflunomide in dialysis patients with rheumatoid arthritis—a pharmacokinetic study. Clin Rheumatol. 2012;32(2):267–70.

    Article  PubMed  Google Scholar 

  18. Arava® (leflunomide): product monograph. Laval: Sanofi-Aventis; 2015. p. 1–70. http://products.sanofi.ca/en/arava.pdf. Accessed 18 Feb 2017.

  19. Kim K-A, Joo H-J, Park J-Y. Effect of ABCG2 genotypes on the pharmacokinetics of A771726, an active metabolite of prodrug leflunomide, and association of A771726 exposure with serum uric acid level. Eur J Clin Pharmacol. 2010;67(2):129–34.

    Article  PubMed  Google Scholar 

  20. Chong A, Zeng H, Knight D, Shen J, Meister G, Williams J, et al. Concurrent antiviral and immunosuppressive activities of leflunomide in vivo. Am J Transplant. 2006;6(1):69–75.

    Article  CAS  PubMed  Google Scholar 

  21. Knight DA, Hejmanowski AQ, Dierksheide JE, Williams JW, Chong AS, Waldman WJ. Inhibition of herpes simplex virus type 1 by the experimental immunosuppressive agent leflunomide. Transplantation. 2001;71(1):170–4.

    Article  CAS  PubMed  Google Scholar 

  22. Schläpfer E, Fischer M, Ott P, Speck RF. Anti-HIV-1 activity of leflunomide: a comparison with mycophenolic acid and hydroxyurea. AIDS. 2003;17(11):1613–20.

    Article  PubMed  Google Scholar 

  23. Liacini A, Seamone ME, Muruve DA, Tibbles LA. Anti-BK virus mechanisms of sirolimus and leflunomide alone and in combination: toward a new therapy for BK virus infection. Transplantation. 2010;90(12):1450–7.

    Article  CAS  PubMed  Google Scholar 

  24. Bernhoff E, Tylden GD, Kjerpeseth LJ, Gutteberg TJ, Hirsch HH, Rinaldo CH. Leflunomide inhibition of BK virus replication in renal tubular epithelial cells. J Virol. 2010;84(4):2150–6.

    Article  CAS  PubMed  Google Scholar 

  25. Josephson MA, Gillen D, Javaid B, Kadambi P, Meehan S, Foster P, et al. Treatment of renal allograft polyoma BK virus infection with leflunomide. Transplantation. 2006;81(5):704–10.

    Article  CAS  PubMed  Google Scholar 

  26. Krisl JC, Taber DJ, Pilch N, Chavin K, Bratton C, Thomas B, et al. Leflunomide efficacy and pharmacodynamics for the treatment of BK viral infection. Clin J Am Soc Nephrol. 2012;7(6):1003–9.

    Article  CAS  PubMed  Google Scholar 

  27. Johnston O, Jaswal D, Gill JS, Doucette S, Fergusson DA, Knoll GA. Treatment of polyomavirus infection in kidney transplant recipients: a systematic review. Transplantation. 2010;89(9):1057–70.

    Article  PubMed  Google Scholar 

  28. Leca N, Muczynski KA, Jefferson JA, de Boer IH, Kowalewska J, Kendrick EA, et al. Higher levels of leflunomide are associated with hemolysis and are not superior to lower levels for BK virus clearance in renal transplant patients. Clin J Am Soc Nephrol. 2008;3(3):829–35.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Lexi-Comp, Inc. (Lexi-Drugs®). Lexi-Comp, Inc.; 2016. https://online.lexi.com/. Accessed 18 Feb 2017.

  30. Vancouver Acute Pharmaceutical Sciences. Special access program & non-formulary drugs. List of monographs. http://www.vhpharmsci.com/PDTM/pdtm-SAP-&-NF-index.htm. Accessed 16 Feb 2016.

  31. Drugs@FDA: FDA approved drug products. http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.SearchAction&SearchTerm=Cidofovir&SearchType=BasicSearch. Accessed 18 Nov 2016.

  32. Sener A, House AA, Jevnikar AM, Boudville N, McAlister VC, Muirhead N, et al. Intravenous immunoglobulin as a treatment for BK virus associated nephropathy: one-year follow-up of renal allograft recipients. Transplantation. 2006;81(1):117–20.

    Article  CAS  PubMed  Google Scholar 

  33. Wittstock M, Benecke R, Zettl UK. Therapy with intravenous immunoglobulins: complications and side-effects. Eur Neurol. 2003;50(3):172–5.

    Article  CAS  PubMed  Google Scholar 

  34. Knoll GA, Humar A, Fergusson D, Johnston O, House AA, Kim SJ, et al. Levofloxacin for BK virus prophylaxis following kidney transplantation: a randomized clinical trial. JAMA. 2014;312(20):2106–14.

    Article  PubMed  Google Scholar 

  35. Zeidan S, Esposito L, Rostaing L, Kamar N. The Achilles tendon of preventing BK virus nephropathy. Transpl Infect Dis. 2013;15(6):E268–9.

    Article  CAS  PubMed  Google Scholar 

  36. Chan V, Charles BG, Tett SE. Rapid determination of the active leflunomide metabolite A77 1726 in human plasma by high-performance liquid chromatography. J Chromatogr B. 2004;803(2):331–5.

    Article  CAS  Google Scholar 

  37. Dias VC, Lucien J, LeGatt DF, Yatscoff RW. Measurement of the active leflunomide metabolite (A77 1726) by reverse-phase high-performance liquid chromatography. Ther Drug Monit. 1995;17(1):84–8.

    Article  CAS  PubMed  Google Scholar 

  38. Parekh JM, Vaghela RN, Sutariya DK, Sanyal M, Yadav M, Shrivastav PS. Chromatographic separation and sensitive determination of teriflunomide, an active metabolite of leflunomide in human plasma by liquid chromatography-tandem mass spectrometry. J Chromatogr B. 2010;878(24):2217–25.

    Article  CAS  Google Scholar 

  39. Rakhila H, Rozek T, Hopkins A, Proudman S, Cleland L, James M, et al. Quantitation of total and free teriflunomide (A77 1726) in human plasma by LC–MS/MS. J Pharm Biomed Anal. 2011;55(2):325–31.

    Article  CAS  PubMed  Google Scholar 

  40. Schmidt A, Schwind B, Gillich M, Brune K, Hinz B. Simultaneous determination of leflunomide and its active metabolite, A77 1726, in human plasma by high-performance liquid chromatography. Biomed Chromatogr. 2003;17(4):276–81.

    Article  CAS  PubMed  Google Scholar 

  41. Sobhani K, Garrett DA, Liu D-P, Rainey PM. A rapid and simple high-performance liquid chromatography assay for the leflunomide metabolite, teriflunomide (A77 1726), in renal transplant recipients. Am J Clin Pathol. 2010;133(3):454–7.

    Article  CAS  PubMed  Google Scholar 

  42. van Roon EN, Yska JP, Raemaekers J, Jansen TLTA, van Wanrooy M, Brouwers JRBJ. A rapid and simple determination of A77 1726 in human serum by high-performance liquid chromatography and its application for optimization of leflunomide therapy. J Pharm Biomed Anal. 2004;36(1):17–22.

    Article  PubMed  Google Scholar 

  43. Hüttemann M, Shipkova M, Klett C, Hasche G, Wilhelm J, Bolley R, et al. Total and free plasma concentrations of the active metabolite of leflunomide in relation to therapeutic outcome in kidney transplant recipients with BK virus nephropathy. Transplant Proc. 2013;45(4):1611–3.

    Article  PubMed  Google Scholar 

  44. Williams JW, Javaid B, Kadambi PV, Gillen D, Harland R, Thistlewaite JR, et al. Leflunomide for polyomavirus type BK nephropathy. N Engl J Med. 2005;352(11):1157–8.

    Article  CAS  PubMed  Google Scholar 

  45. Chan V, Charles BG, Tett SE. Population pharmacokinetics and association between A77 1726 plasma concentrations and disease activity measures following administration of leflunomide to people with rheumatoid arthritis. Br J Clin Pharmacol. 2005;60(3):257–64.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. Li EK, Tam L-S, Tomlinson B. Leflunomide in the treatment of rheumatoid arthritis. Clin Ther. 2004;26(4):447–59.

    Article  CAS  PubMed  Google Scholar 

  47. Miller AE. Teriflunomide: a once-daily oral medication for the treatment of relapsing forms of multiple sclerosis. Clin Ther. 2015;37(10):2366–80.

    Article  CAS  PubMed  Google Scholar 

  48. van Roon EN, Jansen TLTA, van de Laar MAFJ, Janssen M, Yska JP, Keuper R, et al. Therapeutic drug monitoring of A77 1726, the active metabolite of leflunomide: serum concentrations predict response to treatment in patients with rheumatoid arthritis. Ann Rheum Dis. 2005;64(4):569–74.

    Article  PubMed  Google Scholar 

  49. Faguer S, Hirsch HH, Kamar N, Guilbeau-Frugier C, Ribes D, Guitard J, et al. Leflunomide treatment for polyomavirus BK-associated nephropathy after kidney transplantation. Transpl Int. 2007;20(11):962–9.

    Article  CAS  PubMed  Google Scholar 

  50. Teschner S, Gerke P, Geyer M, Wilpert J, Krumme B, Benzing T, et al. Leflunomide therapy for polyomavirus-induced allograft nephropathy: efficient BK virus elimination without increased risk of rejection. Transplant Proc. 2009;41(6):2533–8.

    Article  CAS  PubMed  Google Scholar 

  51. Araya CE, Garin EH, Neiberger RE, Dharnidharka VR. Leflunomide therapy for BK virus allograft nephropathy in pediatric and young adult kidney transplant recipients. Pediatr Transplant. 2010;14(1):145–50.

    Article  PubMed  Google Scholar 

  52. Bechert CJ, Schnadig VJ, Payne DA, Dong J. Monitoring of BK viral load in renal allograft recipients by real-time PCR assays. Am J Clin Pathol. 2010;133(2):242–50.

    Article  CAS  PubMed  Google Scholar 

  53. Cuellar-Rodriguez J, Stephany B, Poggio E, Mossad SB, Goldfarb D, Lard M, et al. Contrasting patterns of viral load response in transplant recipients with BK polyomavirus DNAemia on leflunomide therapy. Clin Transplant. 2013;27(3):E230–6.

    Article  CAS  PubMed  Google Scholar 

  54. Dall A, Hariharan S. BK virus nephritis after renal transplantation. Clin J Am Soc Nephrol. 2008;3(Supplement 2):S68–75.

    Article  PubMed  PubMed Central  Google Scholar 

  55. Drachenberg CB, Papadimitriou JC, Hirsch HH, Wali R, Crowder C, Nogueira J, et al. Histological patterns of polyomavirus nephropathy: correlation with graft outcome and viral load. Am J Transplant. 2004;4(12):2082–92.

    Article  PubMed  Google Scholar 

  56. Beaman JM, Hackett LP, Luxton G, Illett KF. Effect of hemodialysis on leflunomide plasma concentrations. Ann Pharmacother. 2002;36(1):75–7.

    Article  PubMed  Google Scholar 

  57. Russo PA, Wiese MD, Smith MD, Ahern MJ, Barbara JA, Shanahan EM. Leflunomide for inflammatory arthritis in end-stage renal disease on peritoneal dialysis: a pharmacokinetic and pharmacogenetic study. Ann Pharmacother. 2013;47(3):e15.

    Article  PubMed  Google Scholar 

  58. Hirsch HH, Randhawa P, AST Infectious Diseases Community of Practice. BK polyomavirus in solid organ transplantation. Am J Transplant. 2013;13(s4):179–88.

    Article  CAS  PubMed  Google Scholar 

  59. Waldman WJ, Knight DA, Blinder L, Shen J, Lurain NS, Miller DM, et al. Inhibition of cytomegalovirus in vitro and in vivo by the experimental immunosuppressive agent leflunomide. Intervirology. 1999;42(5–6):412–8.

    Article  CAS  PubMed  Google Scholar 

  60. Waldman WJ, Knight DA, Lurain NS, Miller DM, Sedmak DD, Williams JW, et al. Novel mechanism of inhibition of cytomegalovirus by the experimental immunosuppressive agent leflunomide. Transplantation. 1999;68(6):814–25.

    Article  CAS  PubMed  Google Scholar 

  61. Bohanec Grabar P, Grabnar I, Rozman B, Logar D, Tomšič M, Šuput D, et al. Investigation of the influence of CYP1A2 and CYP2C19 genetic polymorphism on 2-cyano-3-hydroxy-N-[4-(trifluoromethyl)phenyl]-2-butenamide (A77 1726) pharmacokinetics in leflunomide-treated patients with rheumatoid arthritis. Drug Metab Dispos. 2009;37(10):2061–8.

    Article  PubMed  Google Scholar 

  62. FDA Center for Drug Evaluation and Research. Sanofi-Aventis. Clinical pharmacology and biopharmaceutics review: teriflunomide. 2001. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202992Orig1s000ClinpharmR.pdf. Accessed 18 Feb 2017.

  63. Bohanec Grabar P, Rozman B, Tomsic M, Suput D, Logar D, Dolzan V. Genetic polymorphism of CYP1A2 and the toxicity of leflunomide treatment in rheumatoid arthritis patients. Eur J Clin Pharmacol. 2008;64(9):871–6.

    Article  CAS  PubMed  Google Scholar 

  64. Filali-Ansary A, Lunven C, Turpault S, Beyer Y-J, O’Brien A, Delfolie A, et al. Dried blood spot methodology in combination with liquid chromatography/tandem mass spectrometry facilitates the monitoring of teriflunomide. Ther Drug Monit. 2016;38(4):471–82.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  65. Suneetha A, Raja RK. Comparison of LC-UV and LC–MS methods for simultaneous determination of teriflunomide, dimethyl fumarate and fampridine in human plasma: application to rat pharmacokinetic study. Biomed Chromatogr. 2016;30(9):1371–7.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, BC, Canada

    Joan C. Y. Ng, Marianna Leung & Mary H. H. Ensom

  2. Providence Health Care, Vancouver, BC, Canada

    Joan C. Y. Ng & Marianna Leung

  3. Transplant Infectious Disease, Division of Infectious Diseases, University of British Columbia, Vancouver, BC, Canada

    Alissa J. Wright

  4. Department of Pharmacy, Children’s and Women’s Health Centre of British Columbia, Vancouver, BC, Canada

    Mary H. H. Ensom

Authors
  1. Joan C. Y. Ng
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Marianna Leung
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Alissa J. Wright
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Mary H. H. Ensom
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mary H. H. Ensom.

Ethics declarations

Funding

No sources of funding were used to assist with the preparation of this review.

Conflict of interest

Ms. Ng, Dr. Leung, Dr. Wright, and Dr. Ensom have no conflicts of interest that are relevant to the content of this review.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ng, J.C.Y., Leung, M., Wright, A.J. et al. Clinical Pharmacokinetic Monitoring of Leflunomide in Renal Transplant Recipients with BK Virus Reactivation: A Review of the Literature. Clin Pharmacokinet 56, 1015–1031 (2017). https://doi.org/10.1007/s40262-017-0521-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40262-017-0521-9

Keywords

Search

Navigation